Logo

Design Therapeutics, Inc.

DSGN

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually le… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$6.02

Price

-11.41%

-$0.77

Market Cap

$342.543m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$588k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$63.488m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.12

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$213.037m

$222.886m

Assets

$9.849m

Liabilities

$1.102m

Debt
Debt to Assets

0.5%

-

Debt to EBITDA
Free Cash Flow

-$50.779m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases